There are some recommendations for interventions, including critically controlling the cumulative dosage of anthracyclines (Chinese Society of Clinical Oncology, Chinese Society of Hematalogy, 2013); using dexrazoxane (Lipshultz et al., 2014); using liposomal anthracyclines (instead of regular anthracyclines) (Gabizon, 2001; Smith et al., 2010; Henriksen, 2017); and using angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers and statins to prevent and treat HF (Huelsenbeck et al., 2011; Bloom et al., 2016). This evidence concerns the gene ACE and hydrops fetalis.